-+ 0.00%
-+ 0.00%
-+ 0.00%

Fulcrum Therapeutics posts corporate presentation on pociredir oral HbF inducer for sickle cell disease

PUBT·04/27/2026 13:18:14
Listen to the news
Fulcrum Therapeutics posts corporate presentation on pociredir oral HbF inducer for sickle cell disease
  • Fulcrum outlined plans to start a potential registration-enabling trial of sickle cell disease candidate pociredir in 2H 2026.
  • Phase 1b PIONEER study completed in Q1 2026.
  • Company flagged 20 mg cohort data showing mean absolute HbF increase of 12.2% to 19.3% at Week 12.
  • Fulcrum reported USD 333.3 million cash as of March 31, 2026, projecting runway into 2029.
  • Pociredir holds Fast Track and Orphan Drug designations, with patent coverage cited through 2040.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.